Medpace initiated with an Outperform at RBC Capital

RBC Capital analyst Ryan Halsted initiated coverage of Medpace (MEDP) with an Outperform rating and $522 price target The company is the most efficient CRO – contract research organization – per employee and most significantly levered to the biopharma end markets where the firm is seeing the strongest green shoots in terms of clinical trial activity, the analyst tells investors in a research note. This is further supporting Medpace segment-leading growth and margins ahead of their larger peers, the firm adds.